Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2025)
Historic Operating Leases for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Q3 2025 value amounting to $21.9 million.
- Arcturus Therapeutics Holdings' Operating Leases fell 1586.18% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year decrease of 1586.18%. This contributed to the annual value of $25.0 million for FY2024, which is 350.87% down from last year.
- Per Arcturus Therapeutics Holdings' latest filing, its Operating Leases stood at $21.9 million for Q3 2025, which was down 1586.18% from $22.9 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' Operating Leases' 5-year high stood at $32.2 million during Q2 2022, with a 5-year trough of $4.1 million in Q1 2022.
- For the 5-year period, Arcturus Therapeutics Holdings' Operating Leases averaged around $21.2 million, with its median value being $25.9 million (2023).
- Its Operating Leases has fluctuated over the past 5 years, first crashed by 2894.92% in 2022, then skyrocketed by 61942.32% in 2023.
- Over the past 5 years, Arcturus Therapeutics Holdings' Operating Leases (Quarter) stood at $4.5 million in 2021, then skyrocketed by 571.17% to $30.2 million in 2022, then fell by 14.26% to $25.9 million in 2023, then dropped by 3.51% to $25.0 million in 2024, then fell by 12.53% to $21.9 million in 2025.
- Its Operating Leases stands at $21.9 million for Q3 2025, versus $22.9 million for Q2 2025 and $24.0 million for Q1 2025.